Regeneron kicks off Phase III trial of COVID-19 antibody cocktail
This follows a positive review from the Independent Data Monitoring Committee of REGN-COV2 Phase I safety results
Read More
Tag: REGN-COV2
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
